The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients

Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):108S-111S. doi: 10.1111/j.1365-2125.1984.tb02442.x.


Indomethacin and sulindac were used as tools to study the role of renal and/or systemic prostaglandins in the pharmacological response to atenolol. Patients receiving chronic treatment with atenolol 100 mg received indomethacin 50 mg twice daily or sulindac 200 mg twice daily in a randomised crossover trial. Indomethacin significantly reduced the antihypertensive action of atenolol while sulindac had no effect. The role that systemic and/or renal prostaglandins may play in the antihypertensive action of atenolol is discussed with reference to renal PGI2 production and inhibition of platelet cyclo-oxygenase.

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / urine
  • Adult
  • Atenolol / pharmacology*
  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Drug Interactions
  • Female
  • Humans
  • Hypertension / physiopathology*
  • Indenes / pharmacology*
  • Indomethacin / pharmacology*
  • Male
  • Middle Aged
  • Random Allocation
  • Renin / blood
  • Sulindac / pharmacology*
  • Thromboxane B2 / blood


  • Indenes
  • Sulindac
  • Atenolol
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha
  • Renin
  • Indomethacin